{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:34:57Z","timestamp":1791261297230,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T00:00:00Z","timestamp":1768089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Research Council of Thailand (NRCT), Mahidol University","award":["N42A650364"],"award-info":[{"award-number":["N42A650364"]}]},{"DOI":"10.13039\/501100004704","name":"National Research Council of Thailand","doi-asserted-by":"crossref","award":["N34E670096"],"award-info":[{"award-number":["N34E670096"]}],"id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100019476","name":"Siriraj Foundation","doi-asserted-by":"publisher","award":["D1671"],"award-info":[{"award-number":["D1671"]}],"id":[{"id":"10.13039\/100019476","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Siriraj Research Funds","award":["R016634006 and R016737004"],"award-info":[{"award-number":["R016634006 and R016737004"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-34331-6","type":"journal-article","created":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T17:04:51Z","timestamp":1768151091000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["B7-H3 and GD2 overexpression as immunotherapeutic targets in retinoblastoma"],"prefix":"10.1038","volume":"16","author":[{"given":"Jatuporn","family":"Sujjitjoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Loon","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katesara","family":"Kongkla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kridtin","family":"Jarutatsanangkoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krittiya","family":"Chongsutakawewong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subongkoch","family":"Subhadhirasakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mongkol","family":"Uiprasertkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suthipol","family":"Udompunturak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutita","family":"Junking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pa-thai","family":"Yenchitsomanus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"La-ongsri","family":"Atchaneeyasakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,11]]},"reference":[{"key":"34331_CR1","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3928\/01913913-20190128-02","volume":"56","author":"R Darwich","year":"2019","unstructured":"Darwich, R. et al. Retinoblastoma incidence trends in Canada: A national comprehensive population-based study. J. Pediatr. Ophthalmol. Strabismus 56, 124\u2013130. https:\/\/doi.org\/10.3928\/01913913-20190128-02 (2019).","journal-title":"J. Pediatr. Ophthalmol. Strabismus"},{"key":"34331_CR2","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1038\/s41388-017-0050-x","volume":"37","author":"ID Fabian","year":"2018","unstructured":"Fabian, I. D. et al. The management of retinoblastoma. Oncogene 37, 1551\u20131560. https:\/\/doi.org\/10.1038\/s41388-017-0050-x (2018).","journal-title":"Oncogene"},{"key":"34331_CR3","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.4103\/ijo.IJO_721_20","volume":"68","author":"D Ancona-Lezama","year":"2020","unstructured":"Ancona-Lezama, D., Dalvin, L. A. & Shields, C. L. Modern treatment of retinoblastoma: A 2020 review. Indian J. Ophthalmol. 68, 2356\u20132365. https:\/\/doi.org\/10.4103\/ijo.IJO_721_20 (2020).","journal-title":"Indian J. Ophthalmol."},{"key":"34331_CR4","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439\u2013448. https:\/\/doi.org\/10.1056\/NEJMoa1709866 (2018).","journal-title":"N. Engl. J. Med."},{"key":"34331_CR5","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1358\/dot.2017.53.11.2725754","volume":"53","author":"Y Liu","year":"2017","unstructured":"Liu, Y., Chen, X., Han, W. & Zhang, Y. Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia. Drugs Today Barc. 53, 597\u2013608. https:\/\/doi.org\/10.1358\/dot.2017.53.11.2725754 (2017).","journal-title":"Drugs Today Barc."},{"key":"34331_CR6","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2217\/fon2021-1090","volume":"18","author":"LD Anderson Jr","year":"2022","unstructured":"Anderson, L. D. Jr. Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma. Future Oncol. 18, 277\u2013289. https:\/\/doi.org\/10.2217\/fon2021-1090 (2022).","journal-title":"Future Oncol."},{"key":"34331_CR7","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","volume":"3","author":"M Sadelain","year":"2013","unstructured":"Sadelain, M., Brentjens, R. & Riviere, I. The basic principles of chimeric antigen receptor design. Cancer Discov. 3, 388\u2013398. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0548 (2013).","journal-title":"Cancer Discov."},{"key":"34331_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100971","volume":"14","author":"J Sujjitjoon","year":"2021","unstructured":"Sujjitjoon, J. et al. GD2-specific chimeric antigen receptor-modified T cells targeting retinoblastoma\u2014Assessing tumor and T cell interaction. Transl. Oncol. 14, 100971. https:\/\/doi.org\/10.1016\/j.tranon.2020.100971 (2021).","journal-title":"Transl. Oncol."},{"key":"34331_CR9","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1158\/2326-6066.CIR-14-0051","volume":"2","author":"N Singh","year":"2014","unstructured":"Singh, N. et al. Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma. Cancer Immunol. Res. 2, 1059\u20131070. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0051 (2014).","journal-title":"Cancer Immunol. Res."},{"key":"34331_CR10","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1186\/s12885-019-6131-1","volume":"19","author":"L Andersch","year":"2019","unstructured":"Andersch, L. et al. CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing. BMC Cancer 19, 895. https:\/\/doi.org\/10.1186\/s12885-019-6131-1 (2019).","journal-title":"BMC Cancer"},{"key":"34331_CR11","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/s43018-020-00119-y","volume":"1","author":"K Wang","year":"2020","unstructured":"Wang, K. et al. GD2-specific CAR T cells encapsulated in an injectable hydrogel control retinoblastoma and preserve vision. Nat. Cancer 1, 990\u2013997. https:\/\/doi.org\/10.1038\/s43018-020-00119-y (2020).","journal-title":"Nat. Cancer"},{"key":"34331_CR12","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1002\/1878-0261.13054","volume":"16","author":"O Dr\u00e4ger","year":"2022","unstructured":"Dr\u00e4ger, O., Metz, K., Busch, M. & D\u00fcnker, N. Role of L1CAM in retinoblastoma tumorigenesis: Identification of novel therapeutic targets. Mol. Oncol. 16, 957\u2013981. https:\/\/doi.org\/10.1002\/1878-0261.13054 (2022).","journal-title":"Mol. Oncol."},{"key":"34331_CR13","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1007\/s00262020-02529-4","volume":"69","author":"L Singh","year":"2020","unstructured":"Singh, L. et al. Clinical relevance of the comparative expression of immune checkpoint markers with the clinicopathological findings in patients with primary and chemoreduced retinoblastoma. Cancer Immunol. Immunother. 69, 1087\u20131099. https:\/\/doi.org\/10.1007\/s00262020-02529-4 (2020).","journal-title":"Cancer Immunol. Immunother."},{"key":"34331_CR14","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1167\/iovs.62.2","volume":"62","author":"C Miracco","year":"2021","unstructured":"Miracco, C. et al. Retinoblastoma is characterized by a cold, CD8+ cell poor, PD-L1- microenvironment, which turns into hot, CD8+ cell rich, PD-L1+ after chemotherapy. Invest. Ophthalmol. Vis. Sci. 62, 6. https:\/\/doi.org\/10.1167\/iovs.62.2 (2021).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"34331_CR15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00262-023-03587-0","volume":"73","author":"T Eichholz","year":"2024","unstructured":"Eichholz, T. et al. Targeted therapies in retinoblastoma: GD2-directed immunotherapy following autologous stem cell transplantation and evaluation of alternative target B7\u2013H3. Cancer Immunol. Immunother. 73, 19. https:\/\/doi.org\/10.1007\/s00262-023-03587-0 (2024).","journal-title":"Cancer Immunol. Immunother."},{"key":"34331_CR16","doi-asserted-by":"publisher","first-page":"10185","DOI":"10.1038\/s41598-02067101-7","volume":"10","author":"B Ganesan","year":"2020","unstructured":"Ganesan, B., Parameswaran, S., Sharma, A. & Krishnakumar, S. Clinical relevance of B7H3 expression in retinoblastoma. Sci. Rep. 10, 10185. https:\/\/doi.org\/10.1038\/s41598-02067101-7 (2020).","journal-title":"Sci. Rep."},{"key":"34331_CR17","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1167\/iovs.04-0591","volume":"18","author":"M Mitra","year":"2012","unstructured":"Mitra, M. et al. EpCAM is a putative stem marker in retinoblastoma and an effective target for T-cell-mediated immunotherapy. Mol. Vis. 18, 290\u2013308. https:\/\/doi.org\/10.1167\/iovs.04-0591 (2012).","journal-title":"Mol. Vis."},{"key":"34331_CR18","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1093\/ajcp\/96.2.248","volume":"96","author":"H Sariola","year":"1991","unstructured":"Sariola, H., Terava, H., Rapola, J. & Saarinen, U. M. Cell-surface ganglioside GD2 in the immunohistochemical detection and differential diagnosis of neuroblastoma. Am. J. Clin. Pathol. 96, 248\u2013252 (1991).","journal-title":"Am. J. Clin. Pathol."},{"key":"34331_CR19","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.1182\/blood-2006-08-039347","volume":"109","author":"C Martinez","year":"2007","unstructured":"Martinez, C., Hofmann, T. J., Marino, R., Dominici, M. & Horwitz, E. M. Human bone marrow mesenchymal stromal cells express the neural ganglioside GD2: A novel surface marker for the identification of MSCs. Blood 109, 4245\u20134248. https:\/\/doi.org\/10.1182\/blood-2006-08-039347 (2007).","journal-title":"Blood"},{"key":"34331_CR20","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3892\/mmr_00000248","volume":"3","author":"VE Laurent","year":"2010","unstructured":"Laurent, V. E. et al. Optimization of molecular detection of GD2 synthase mRNA in retinoblastoma. Mol. Med. Rep. 3, 253\u2013259. https:\/\/doi.org\/10.3892\/mmr_00000248 (2010).","journal-title":"Mol. Med. Rep."},{"key":"34331_CR21","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1002\/ijc.2910530614","volume":"53","author":"J Portoukalian","year":"1993","unstructured":"Portoukalian, J., David, M. J., Gain, P. & Richard, M. Shedding of GD2 ganglioside in patients with retinoblastoma. Int. J. Cancer 53, 948\u2013951. https:\/\/doi.org\/10.1002\/ijc.2910530614 (1993).","journal-title":"Int. J. Cancer"},{"key":"34331_CR22","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1097\/00043426-200606000-00009","volume":"28","author":"GL Chantada","year":"2006","unstructured":"Chantada, G. L. et al. An aggressive bone marrow evaluation including immunocytology with GD2 for advanced retinoblastoma. J. Pediatr. Hematol. Oncol. 28, 369\u2013373. https:\/\/doi.org\/10.1097\/00043426-200606000-00009 (2006).","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"34331_CR23","doi-asserted-by":"publisher","first-page":"15441","DOI":"10.18632\/oncotarget.14487","volume":"8","author":"DH Jo","year":"2017","unstructured":"Jo, D. H. et al. L1 increases adhesion mediated proliferation and chemoresistance of retinoblastoma. Oncotarget 8, 15441\u201315452. https:\/\/doi.org\/10.18632\/oncotarget.14487 (2017).","journal-title":"Oncotarget"},{"key":"34331_CR24","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1158\/1078-0432.CCR-16-0354","volume":"23","author":"A Kunkele","year":"2017","unstructured":"Kunkele, A. et al. Preclinical assessment of CD171-directed CAR T-cell adoptive therapy for childhood neuroblastoma: CE7 epitope target safety and product manufacturing feasibility. Clin. Cancer Res. 23, 466\u2013477. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0354 (2017).","journal-title":"Clin. Cancer Res."},{"key":"34331_CR25","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1038\/sj.onc.1210076","volume":"26","author":"MS Sebens","year":"2007","unstructured":"Sebens, M. S. et al. Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells. Oncogene 26, 2759\u20132768. https:\/\/doi.org\/10.1038\/sj.onc.1210076 (2007).","journal-title":"Oncogene"},{"key":"34331_CR26","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.ygyno.2006.08.038","volume":"104","author":"A Stoeck","year":"2007","unstructured":"Stoeck, A. et al. L1-CAM in a membrane-bound or soluble form augments protection from apoptosis in ovarian carcinoma cells. Gynecol. Oncol. 104, 461\u2013469. https:\/\/doi.org\/10.1016\/j.ygyno.2006.08.038 (2007).","journal-title":"Gynecol. Oncol."},{"key":"34331_CR27","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.neuint.2012.08.011","volume":"61","author":"J Held-Feindt","year":"2012","unstructured":"Held-Feindt, J. et al. The neural adhesion molecule L1CAM confers chemoresistance in human glioblastomas. Neurochem. Int. 61, 1183\u20131191. https:\/\/doi.org\/10.1016\/j.neuint.2012.08.011 (2012).","journal-title":"Neurochem. Int."},{"key":"34331_CR28","doi-asserted-by":"publisher","first-page":"374","DOI":"10.4161\/cam.20832","volume":"6","author":"H Kiefel","year":"2012","unstructured":"Kiefel, H. et al. L1CAM: A major driver for tumor cell invasion and motility. Cell Adh. Migr. 6, 374\u2013384. https:\/\/doi.org\/10.4161\/cam.20832 (2012).","journal-title":"Cell Adh. Migr."},{"key":"34331_CR29","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12943-023-01751-9","volume":"22","author":"AA Getu","year":"2023","unstructured":"Getu, A. A. et al. New frontiers in immune checkpoint B7\u2013H3 (CD276) research and drug development. Mol. Cancer 22, 43. https:\/\/doi.org\/10.1186\/s12943-023-01751-9 (2023).","journal-title":"Mol. Cancer"},{"key":"34331_CR30","doi-asserted-by":"publisher","first-page":"4607","DOI":"10.1167\/iovs.06-0181","volume":"47","author":"Y Usui","year":"2006","unstructured":"Usui, Y. et al. Expression of costimulatory molecules on human retinoblastoma cells Y-79: Functional expression of CD40 and B7H1. Invest. Ophthalmol. Vis. Sci. 47, 4607\u20134613. https:\/\/doi.org\/10.1167\/iovs.06-0181 (2006).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"34331_CR31","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1002\/eji.200839028","volume":"39","author":"J Leitner","year":"2009","unstructured":"Leitner, J. et al. B7\u2013H3 is a potent inhibitor of human T-cell activation: No evidence for B7\u2013H3 and TREML2 interaction. Eur. J. Immunol. 39, 1754\u20131764. https:\/\/doi.org\/10.1002\/eji.200839028 (2009).","journal-title":"Eur. J. Immunol."},{"key":"34331_CR32","doi-asserted-by":"publisher","first-page":"11472","DOI":"10.1038\/s41598-019-47910-1","volume":"9","author":"A De Sousa Linhares","year":"2019","unstructured":"De Sousa Linhares, A. et al. Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1\/PD-L1 signaling. Sci. Rep. 9, 11472. https:\/\/doi.org\/10.1038\/s41598-019-47910-1 (2019).","journal-title":"Sci. Rep."},{"key":"34331_CR33","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.1200\/JCO.23.02229","volume":"42","author":"N Pinto","year":"2024","unstructured":"Pinto, N. et al. STRIvE-02: A first-in-human phase I study of systemically administered B7\u2013H3 chimeric antigen receptor T cells for patients with relapsed\/refractory solid tumors. J. Clin. Oncol. 42, 4163\u20134172. https:\/\/doi.org\/10.1200\/JCO.23.02229 (2024).","journal-title":"J. Clin. Oncol."},{"key":"34331_CR34","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","volume":"15","author":"RG Majzner","year":"2019","unstructured":"Majzner, R. G. et al. CAR T cells targeting B7\u2013H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clin. Cancer Res. 15, 2560\u20132574. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0432 (2019).","journal-title":"Clin. Cancer Res."},{"key":"34331_CR35","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/s43018-021-00244-2","volume":"2","author":"K Hirabayashi","year":"2021","unstructured":"Hirabayashi, K. et al. Dual targeting CAR-T cells with optimal costimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors. Nat. Cancer 2, 904\u2013918. https:\/\/doi.org\/10.1038\/s43018-021-00244-2 (2021).","journal-title":"Nat. Cancer"},{"key":"34331_CR36","doi-asserted-by":"publisher","first-page":"595624","DOI":"10.1101\/2024.05.23.595624","volume":"30","author":"ZT Rosenkrans","year":"2024","unstructured":"Rosenkrans, Z. T. et al. Targeting both GD2 and B7\u2013H3 using bispecific antibody improves tumor selectivity for GD2-positive tumors. bioRxiv. 30, 595624. https:\/\/doi.org\/10.1101\/2024.05.23.595624 (2024).","journal-title":"bioRxiv."},{"key":"34331_CR37","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1158\/1078-0432.CCR-24-0221","volume":"30","author":"G Pascual-Pasto","year":"2024","unstructured":"Pascual-Pasto, G. et al. Targeting GPC2 on intraocular and CNS metastatic retinoblastomas with local and systemic delivery of CAR T cells. Clin. Cancer Res. 30, 3578\u20133591. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-0221 (2024).","journal-title":"Clin. Cancer Res."},{"key":"34331_CR38","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12014-016-9128-7","volume":"13","author":"R Danda","year":"2016","unstructured":"Danda, R. et al. Proteomic profiling of retinoblastoma by high resolution mass spectrometry. Clin. Proteom. 13, 29. https:\/\/doi.org\/10.1186\/s12014-016-9128-7 (2016).","journal-title":"Clin. Proteom."},{"key":"34331_CR39","doi-asserted-by":"publisher","first-page":"e1700101","DOI":"10.1002\/prca.201700101","volume":"12","author":"R Danda","year":"2018","unstructured":"Danda, R. et al. Membrane proteome of invasive retinoblastoma: Differential proteins and biomarkers. Proteomics Clin. Appl. 12, e1700101. https:\/\/doi.org\/10.1002\/prca.201700101 (2018).","journal-title":"Proteomics Clin. Appl."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34331-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34331-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34331-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T10:01:05Z","timestamp":1769767265000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34331-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,11]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["34331"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-34331-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,11]]},"assertion":[{"value":"27 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4210"}}